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Abstract (250) 
 
Background: High-sensitivity cardiac troponin T (hs-cTnT) blood concentrations were 
shown to exhibit a diurnal rhythm, characterized by gradually decreasing concentrations 
throughout daytime, rising concentrations during nighttime and peak concentrations in 
the morning. We aimed to investigate whether this also applies to (h)s-cTnI assays and 
whether it would affect diagnostic accuracy for acute myocardial infarction (AMI). 
Methods: Blood concentrations of cTnI were measured at presentation and after 1h 
using four different cTnI assays: three commonly used sensitive (s-cTnI Architect, Ultra 
and Accu) and one experimental high-sensitivity assay (hs-cTnI Accu) in a prospective 
multicenter diagnostic study of patients presenting to the emergency department with 
suspected AMI. These concentrations and their diagnostic accuracy for AMI (quantified 
by the area under the curve (AUC)) were compared between morning (11 p.m. to 2 p.m.) 
and evening (2 p.m. to 11 p.m.) presenters.  
Results: Among 2601 patients, AMI was the final diagnosis in 17.6% of patients. 
Concentrations of (h)s-cTnI as measured using all four assays were comparable in 
patients presenting in the morning versus patients presenting in the evening. Diagnostic 
accuracy for AMI of all four (h)s-cTnI assays were high and comparable between 
patients presenting in the morning versus presenting in the evening (AUC at 
presentation: 0.90 vs 0.93 for s-cTnI Architect; 0.91 vs 0.94 for s-cTnI Ultra; 0.89 vs 0.94 
for s-cTnI Accu; 0.91 vs 0.94 for hs-cTnI Accu). 
Conclusions: Cardiac TnI does not seem to express a diurnal rhythm. Diagnostic 
accuracy for AMI is very high and does not differ with time of presentation. 
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Translational aspect of this work 
Hs-cTnT blood concentrations were shown to exhibit a diurnal rhythm, this has been 
proven to have no effect on diagnostic accuracy for AMI. Whether this also applies to 
(h)cTnI assays has not been investigated yet.  
There was no difference in cTnI concentrations between morning and evening 
presenters in all diagnostic groups. The diagnostic accuracy for AMI was very high and 
similar in both time frames. These findings indicate that (h)s-cTnI expresses no circadian 
rhythm and is safe in use at all time of the day. 
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1. Introduction 
 
Acute myocardial infarction (AMI) is a major cause of cardiovascular death and disability 
worldwide [1]. Rapid identification of AMI is of paramount clinical importance for the 
timely initiation of effective treatment and based on three diagnostic cornerstones: 
clinical assessment, electrocardiography (ECG) and cardiac troponin (cTn) as a 
quantitative marker of cardiomyocyte injury [2]. 
The current clinical use of cTn is based on the assumption that cTn blood 
concentrations are similar at different times of the day allowing the use of standardized 
cut-off levels (e.g. the 99th percentile) irrespective of the time of day [1–6]. The clinical 
introduction of high-sensitivity cTn (hs-cTn) assays, which allow the precise 
quantification of cTn even in the normal range, has enabled investigators to actually test 
this assumption. In fact, the dogma of random fluctuation around a homeostatic set-
point of cTnT and cTnI blood concentrations was recently challenged by the intriguing 
observation that hs-cTnT exhibited a diurnal rhythm in a small group of male subjects 
with type 2 diabetes [7]. The diurnal hs-cTnT rhythm was characterized by peak-levels 
during morning hours, a gradual decrease during the day with lower levels in the evening 
and increasing concentrations during nighttime. While the pathophysiological and 
evolutionary reasons for this phenomenon are still unknown, it could affect the early 
diagnosis of AMI in two ways: first, higher cTnT blood concentrations in the morning in 
non-AMI conditions would reduce the difference between cTnT in non-AMI versus AMI 
and thereby reduce diagnostic accuracy of cTnT blood concentrations; second, the 
rising pattern of cTnT due to a circadian rhythm in the night could reduce the diagnostic 
accuracy of cTnT changes from the first to the second blood draw, which complement 
absolute concentrations. A second pilot study could not find a circadian rhythm for cTnI 
when measured with two specific cTnI assays [8]. Given the poor standardization of cTnI 
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assays and the enormous possible clinical consequences of such a circadian rhythm for 
cTnI, the most commonly used analyte in the early diagnosis of AMI worldwide, 
substantial uncertainty remains regarding this phenomenon. 
We therefore aimed to address this important gap in knowledge by assessing 
differences in cTnI blood concentrations and their possible impact on the diagnostic 
accuracy for AMI between patients presenting in the morning versus those presenting 
in the evening hours using four (h)s-cTnI assays not previously investigated regarding 
circadian rhythm. 
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2. Methods 
 
2. 1 Study design 
Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) 
(http://clinicaltrials.gov/show/NCT00470587) is an ongoing prospective diagnostic 
multicenter study enrolling patients aged at least 18 years presenting to the emergency 
department (ED) with symptoms suggestive for AMI and onset or peak of symptoms 
within 12 hours prior to presentation in twelve centers in five countries in Europe 
(Switzerland, Spain, Italy, Czech Republic, Poland) [9–11].   
Patients were included irrespective of their renal function, only terminal kidney failure 
requiring regular dialysis was an exclusion criterion. For this analysis, patients were also 
excluded if A) time of presentation to the ED was missing, B) the investigated cTnI 
values were not available, C) the final diagnosis remained unclear after central 
adjudication and at least one hs-cTnT was elevated, thereby possibly indicating AMI 
and D) patients had a final diagnosis of ST-elevation MI, as cTn is considered of limited 
utility in the early diagnosis of these patients (Figure 1S, Online Suppl.). Patients were 
classified according to their time of presentation to the ED in two timeframes that were 
derived from the acrophase and bathyphase of the fitted cosine model of the observed 
diurnal rhythm of cTnT [7] to comprise the supposed highest and lowest levels of cTn: 
a cTn high-level phase in the morning (11:00 pm till 2:00 pm) and a cTn low-level phase 
in the evening (2:00 pm till 11:00pm) [7,8]. This strategy allowed us to make sure to 
include the supposed high and low of cTn as almost centering the respective time 
window and to allow enough patients in both time frames for a reasonable analysis 
since during nighttime less patients were included in relation to daytime. 
For this study, blood sampling was performed at presentation to the ED (t1) as 
well as one hour thereafter (t2). 
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The study complies to the principles of the Declaration of Helsinki and was 
approved by the local ethic committee. All patients provided written informed consent. 
 
 
2.2 Routine clinical assessment 
All patients underwent a clinical assessment that included medical history, physical 
examination, 12-lead ECG, continuous ECG monitoring, pulse oximetry, standard blood 
test, and chest radiography. Levels of the cTn used for the clinical management of patients 
(various assays, see online appendix) were measured at presentation and serially 
thereafter as long as clinically indicated. Treatment of patients was left at the discretion of 
the attending physician. 
 
2.3 Adjudicated diagnosis and follow-up 
Adjudication of the final diagnosis was performed centrally in a core lab (University 
Hospital Basel) for all patients. In order to take advantage of the higher sensitivity and 
higher overall diagnostic accuracy offered by high-sensitivity cTn (hs-cTn) [2–6,12,13], 
the adjudicating cardiologists had access to serial levels of cTn/hs-cTn measured locally 
as part of routine clinical care as well as serial hs-cTnT concentrations measured in a 
central laboratory from the serial study blood samples. Two independent cardiologists 
reviewed all available medical records - patient history, physical examination, results of 
laboratory testing, radiologic testing, ECG, echocardiography, cardiac exercise test, lesion 
severity and morphology in coronary angiography - pertaining to the patient from the time 
of ED presentation to 90-day follow up. In situations of disagreement about the diagnosis, 
cases were reviewed and discussed with a third cardiologist.  
 AMI was defined as recommended in current guidelines [2,14]. In brief, AMI was 
diagnosed when there was evidence of myocardial necrosis in a clinical setting 
consistent with myocardial ischemia. Necrosis was diagnosed by a rising or falling 
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pattern of cTn with at least one value above the 99th percentile [2,15]. Unstable angina 
was diagnosed in patients with normal cTn levels and typical angina at rest, a 
deterioration of a previously stable angina, in cases of positive cardiac exercise testing 
or cardiac catheterization with coronary arteries found to have stenosis ≥70%, and in 
ambiguous cases in which follow-up information revealed acute myocardial infarction or 
a sudden unexpected cardiac death within 90 days. Further predefined diagnostic 
categories included cardiac but not coronary symptoms (e.g., perimyocarditis, 
tachyarrhythmias, heart failure) and non-cardiac symptoms (e.g., muscular, pulmonary, 
gastrointestinal). If AMI was excluded in the ED but symptoms were highly suggestive 
of unstable angina, but no sufficient further work-up was performed to either reliably 
diagnose or exclude unstable angina, symptoms were classified as being of unknown 
origin. After hospital discharge, patients were followed at 3, 12 and 24 months by 
telephone or in written form, performed by trained researchers. 
 
2.4 Laboratory measurement  
Study blood samples were centrifuged and plasma/serum was frozen at -80°C until cTnI 
concentrations were measured in a blinded fashion by a core laboratory team. For this 
study, three sensitive assays (s-cTnI Abbott Architect (9ng/L, 28ng/L, 14% [16]), s-cTnI 
Siemens Ultra (6ng/L, 40ng/l, 8.8% [16], s-cTnI Beckman Accu (10ng/L, 40ng/L, 14% 
[16]) and one high-sensitivity assay (hs-cTnI Beckman Accu (2ng/L, 8.6ng/L, 10% [16]) 
were used with the indicated limit of detection (LoD), 99th percentile and coeffient of 
variation at the 99th percentile respectively. The limit of blank (LoB) and LoD of hs-cTnT 
(Elecsys) were determined to be 3ng/l and 5ng/l, the 99th percentile of a healthy 
reference population was reported at 14ng/l with an imprecision corresponding to 10% 
coefficient of variation (CV) at 13ng/l [16,17]. 
 The estimated glomerular filtration rate (eGFR) was calculated according to the 
modification of diet in renal disease study (MDRD) [18]. 
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2.5 Statistical analysis 
Categorical variables are reported as numbers and percentages, continuous Gaussian 
variables as means with standard deviation (SD), and non-Gaussian variables as 
medians with interquartile range (IQR). Comparisons between groups were made using 
Student`s t-test, Mann-Whitney U test and Kruskal-Wallis test as appropriate. 
Absolute, unsigned change levels between 0h and 1h cTn were calculated (t2-t1). 
Median levels for 0h, 1h and absolute changes were compared in patients presenting in 
the morning versus evening group according to the five diagnostic groups. We 
hypothesized that if a circadian rhythm would be present for cTnI, it should become 
visible in patients with non-cardiac causes of chest discomfort and in patients with 
unstable angina, the two acute disorders in whom the cTnI concentration determined at 
presentation would be unchanged by the acute chest pain episode, but reflecting the 
“normal” circadian concentration. 
Receiver operating characteristics curves (AUC) were constructed to assess sensitivity 
and specificity of cTnI for the diagnosis of AMI in morning and evening presenters. 
Comparison of independent AUC was performed as recommended by Hanley and 
McNeil [19]. Predefined subgroup analysis was performed in early presenters (defined 
as time from chest pain onset to presentation ≤3h) as a possible circadian rhythm in 
cTnI would be expected to particularly affect the diagnostic accuracy for AMI in this 
challenging subgroup. 
 All statistical analyses were performed using SPSS version 22 for Windows 
(Chicago, USA) and MedCalc 10.3.0 (Ostend, Belgium). All hypothesis testing was 2-
tailed and a significance level of less than 0.05 was considered statistically significant. 
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3. Results 
 
3.1 Patient characteristics 
Between April 2006 and June 2013, a total of 2601 enrolled patients qualified for this 
analysis. Baseline values of s-cTnI Abbott Architect were available in 1266 patients 
(morning presenters 984 vs evening presenters 282 pts.), in 2567 patients for s-cTnI 
Siemens Ultra (1912 vs 655 pts.), in 1107 patients for s-cTnI Beckmann Accu (856 vs 
251 pts.) and 1104 patients for hs-cTnI Beckman Accu (854 vs 250 pts.).  
The adjudicated final diagnosis was AMI in 17.6% of patients, unstable angina in 
10.1%, cardiac non-coronary disease in 14.3%, non-cardiac chest pain in 53.2% and 
unknown (but not AMI) in 4.8% in the whole cohort. Overall, baseline characteristics in 
morning and evening presenters were comparable (Table 1), as were the baseline 
characteristics in the subgroups of patients with 0h values of the respective assays 
available (Table 1S, Online Supplement). 
 
3.2 Blood concentrations of cTnI 
Blood concentrations of cTnI at presentation, at 1h, and their absolute change at 1h 
were comparable between morning versus evening presenting patients for all assays 
among the five diagnosis groups (Table 2S, Online Suppl.), also in patients adjudicated 
to have non-cardiac chest pain (Figure 1) and unstable angina.  
 
3.3 Impact on diagnostic accuracy for AMI 
For all assays, diagnostic accuracy for AMI as quantified by the AUC for cTnI 
concentrations at presentation was very high in morning and evening presenters: 0.90 
vs 0.93 for s-cTnI Abbott Architect, 0.91 vs 0.94 for s-cTnI Siemens Ultra, 0.89 vs 0.94 
for s-cTnI Beckman Accu and 0.91 vs 0.94 for hs-cTnI Beckman Accu (p for 
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comparison=ns) (Table 2A, Figure 2). The AUC at 1h and for the combination of 
absolute changes with baseline values was also very high and comparable among 
patients presenting in the morning versus patients presenting in the evening hours 
(Table 2A).  
 Among the subgroup of early presenting patients (≤3 hours since symptom onset, 
n=1401, 53.9%) similar results were observed (Table 2B). Nevertheless, there was one 
exception: the AUC at presentation for cTnI Siemens Ultra was significantly lower for 
patients presenting morning as compared to those presenting in the evening hours (0.89 
(95%Cl 0.87-0.91) vs 0.95 (95%Cl 0.92-0.97)).  
 
3.4 Prognostic accuracy of cTnI for the prediction of all-cause mortality  
As shown in Table 3S in the Online Supplement, there was no difference in accuracy 
regarding the prediction of all-cause mortality within 2 years between early-morning and 
evening presenters in all assessed (h)s-cTnI assays.  
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4. Discussion 
 
In a large diagnostic multicenter study enrolling patients presenting with suspected AMI 
to the ED we assessed the possible presence of a circadian rhythm of cTnI by using 
three sensitive and one high-sensitivity cTnI assay. We evaluated differences in cTnI 
blood concentrations and their possible impact on the diagnostic accuracy for AMI 
between patients presenting in the morning versus those presenting in the evening. We 
report three major findings:  
 First, cTnI blood concentrations at all time points as well as their absolute 
changes as measured with all four assays were similar in morning and evening 
presenters in all adjudicated diagnosis groups, particularly also in patients with non-
cardiac chest pain and unstable angina, the two diagnostic groups most likely to display 
a circadian rhythm. This finding strongly argues against the presence of a circadian 
rhythm for cTnI as quantified by the four cTnI assays tested. Second, diagnostic 
accuracy of all investigated assays for AMI was very high and comparable between 
patients presenting in the morning versus patients presenting in the evening. Third, 
similar results were reproducible in the subgroup of early presenting patients with the 
exception of s-cTnI Ultra at presentation.  
These findings extend and corroborate previous pilot studies examining circadian 
rhythms of cTnT and cTnI [7,8] and further support the evolving concept that relevant 
pathophysiological differences underlie the release of cTnT and cTnI into the circulation, 
as well as possibly their clearance [7,8,16,20]. As the circulating cTnT and cTnI 
concentration is defined by the extent of release and clearance, this study does not allow 
to quantify the influence of both processes on the diurnal cTnT rhythm [8]. The 
rhythmicity observed for cTnT is in line with the circadian organization of the 
cardiovascular system [21]. Synchronizing physiological functions to the natural 24h 
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light-dark cycle, for example by upregulating body temperature and blood pressure 
before the time of awakening, anticipates to the demands of daytime activities [8].  
Circadian rhythmicity has in addition been described for many cardiovascular traits: 
heart rate, sympathetic activity, vascular resistance, the renin-angiotensin-aldosteron 
system, prothrombotic tendency, platelet aggregability and the fibrinolytic system [8,22–
24]. Identical to cTnT concentrations, all these components exhibit peak activity in 
(early) morning hours. The physiological rhythmicity of these cardiovascular 
components is reflected in the increasing intensity of cardiovascular events in the 
morning hours [25–27]. For example, the incidence of AMI, sudden cardiac death and 
stroke display a significant 24h variation, characterized by a higher frequency in morning 
hours [25–27].  
As the blood concentration of cTnI reflects the balance between release from 
cardiomyocytes into the systemic circulation and the clearance from blood, the absence 
of a circadian rhythm for cTnI in its blood concentration as documented by this study 
and a pilot study [7] does not necessarily prove the absence of a circadian rhythm in the 
release in cTnI. Assuming that the magnitude of clearance of cTnI from blood underlies 
a similar circadian pattern as its release from cardiomyocytes, then the net result could 
still be constant blood concentrations. The difference between cTnI and cTnT [7,8] could 
therefore still be attributable to differences in their clearance mechanisms.  
The clinical availability of hs-cTn assays for cTnT and cTnI has allowed 
translational and clinical research to provide first insights into differences between cTnT 
and cTnI [28–32]. Next to multiple and important similarities including a very high 
correlation in several clinical settings including suspected AMI in the ED [32], nearly 
exclusive organ specificity for the heart, very high diagnostic accuracy for AMI, and 
integral part of the universal definition of MI [2], recently observed differences include: 
first, higher prognostic accuracy for death for cTnT [32], higher prognostic accuracy for 
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future MI for cTnI [32], possible higher diagnostic accuracy in early presenters for cTnI 
[32], and circadian rhythm for cTnT but not cTnI [7,8]. 
The reasons for these differences are largely unknown. Both cTnT and cTnI 
modulate the contractile function of the sarcomere and therefore play an important role 
in the regulation of the excitation-contraction coupling in the heart [33]. However, they 
differ in regards of quantity of release into the bloodstream: cTnT content per gram of 
myocardium is roughly twice that of cTnI (10mg/g versus 4-6mg/g) [33]. Further, release 
kinetics differ: the part of cTn which occurs as a free cytosolic component (cTnT: 7%, 
cTnI: 3.5%) is released earlier into the blood stream in case of cellular degradation 
compared to the cTn fraction, which is bound in the sarcomere [34,35]. Additionally, 
differences in clearance of the two molecules might play a role: cTnT seems to have a 
higher molecular weight than cTnI (35kDa versus 23-24kDa) [33]. It is yet thought that 
cTnT as well as cTnI are cleared by the kidney, but in patients with renal failure, cTnT 
is increased more frequently than cTnI [35]. It might therefore be possible that a diurnal 
change in cTnT clearance could contribute to the circadian variability described [7,8,36] 
previously.  
Moreover, specific characteristics of the individual cTn assays used might have 
contributed to the findings of this study. Besides the intraindividual biological variation, 
also interindividual variation as well as analytical variation, expressed by the coefficient 
of variation, must be considered when interpreting serially measured cTn values. As the 
hs-cTnI assay used in this study had even higher precision as the hs-cTnT assay used 
to detect the circadian rhythm for cTnT [7], this aspect does not seem to be responsible 
for the observed difference. 
In the subgroup of early presenters, the AUC for the 0h concentrations of s-cTnI 
Ultra was lower for morning compared to evening presenting patients. Although this could have 
been attributable to a circadian rhythm with higher blood concentrations in non-AMI 
patients in the morning, it seems most likely a chance finding as no difference in absolute 
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s-cTnI ultra blood concentrations were observed in non-AMI patients including patients 
with non-cardiac chest pain and patients with unstable angina at presentation and at 1h.  
Scrutiny regarding possible confounders in blood concentrations of hs-cTnT 
and hs-cTnI is timely as several additional indications for clinical use beyond the 
detection of AMI have recently emerged, including the detection of exercise-induced 
myocardial ischemia and the quantification of myocardial end organ damage 
secondary to arterial hypertension or diabetes mellitus [37–39]. These indications 
have in common, that they rely on the ability to detect minuscule differences in cTnT 
and cTnI blood concentrations in the normal range. Presence of a circadian rhythm 
for cTnT or cTnI, as well as any other confounder would therefore be expected to 
have an even larger detrimental effect on these evolving indications as compared to 
the use of cTnT and cTnI in the detection of AMI [7,8]. 
Several limitations of this study merit consideration. First, we evaluated patients 
presenting with acute chest discomfort to the ED. It is unknown whether our findings can 
be extrapolated to patients presenting to primary care. Second, we cannot comment on 
a circadian rhythm in patients with terminal kidney failure requiring dialysis, since these 
were excluded from our study. Third, the methodology of this study focuses on inter-
individual comparisons, as these are of great relevance when considering the current 
definition of MI, which uses as a mandatory criteria an elevation in cTn above a general 
cut-off level (the 99th percentile). Additional studies focusing on intra-individual 
comparisons will provide additional insights.   
In conclusion, in contrast to cTnT, cTnI does not seem to have a clinically relevant 
circadian rhythm. Diagnostic accuracy of cTnI is very high and does not differ 
significantly with time of presentation to the ED. 
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Tables 
 
 
Table 1: Baseline characteristics of all patients  
 
 
all patients, 
n=2601 
morning presentersa, 
n=1935 
evening presentersb, 
n=666 
p-
value 
Age (years) 62 (49.0-74.0) 62.0 (50.0-75.0) 59.5 (48.0-72.0) 0.01 
Women, n (%) 822 (31.6) 613 (31.7) 209 (31.4) 0.4 
Body-mass index (kg/m²) 26.4 (23.9-29.6) 26.3 (23.8-29.6) 26.7 (24.1-29.6) 0.2 
eGFR (ml/min/1.7) 85.4 (69.4-101.5) 85.1 (69.4-101.5) 86 (69.4-101.5) 0.4 
Risk factors, n (%) 
   
  
Hypertension 1605 (61.7) 1205 (62.3) 400 (60.1) 0.3 
Hypercholesterolemia 1308 (50.3) 973 (50.3) 335 (50.3) 0.9 
Diabetes mellitus 443 (17.0) 337 (17.4) 106 (15.9) 0.4 
current or previous smoking 1619 (62.2) 1192 (61.6) 427 (64.1) 0.2 
Family history 690 (26.5) 502 (25.9) 188 (28.2) 0.2 
History, n (%) 
   
  
Coronary artery disease 905 (34.8) 682 (35.2) 223 (33.5) 0.4 
previous AMI 613 (23.6) 468 (24.2) 145 (21.8) 0.2 
previous revascularization 728 (28.0) 541 (28.0) 187 (28.1) 1.0 
peripheral artery disease 155 (6.0) 113 (5.8) 42 (6.3) 0.7 
previous stroke 142 (5.5) 110 (5.7) 32 (4.8) 0.4 
ECG findings, n (%) 
   
  
Left bundle branch block 26 (1.0) 19 (1.0) 7 (1.1) 0.9 
ST-segment depression 263 (10.1) 193 (10.0) 70 (10.5) 0.7 
T-wave inversion 334 (12.8) 240 (12.4) 94 (14.1) 0.3 
Medication at presentation, n 
(%) 
   
  
Aspirin 952 (36.6) 717 (37.1) 235 (35.3) 0.4 
Beta-Blockers 904 (34.8) 684 (35.3) 220 (33.0) 0.3 
Statins 932 (35.8) 699 (36.1) 233 (35.0) 0.6 
ACEIs/ARBs 1003 (38.6) 752 (38.9) 251 (37.7) 0.6 
     
 
eGFR=estimated glomerular filtration rate , AMI=acute myocardial infarction , 
ECG=electrocardiogramm , ACEI=angiotensin-converting enzyme inhibitor , 
ARB=angiotensin-II receptor blocker 
 
a Morning: 11:00 P.M – 2:00 P.M. 
b Evening = 2:00 P.M. – 11:00 P.M 
 
 
 
 Table 2A: Comparison of diagnostic accuracy for AMI as quantified by the area under 
the receiver-operating characteristics curve in morning and evening presenters 
 
 AUC (95%CI) AUC (95%CI)  
 Morninga Eveningb P-value 
s-cTnI Abbott Architect    
0h 0.90 (0.88-0.92) 0.93 (0.90-0.96) 0.3 
1h 0.94 (0.92-0.95) 0.97 (0.93-0.99) 0.3 
0h + ∆1h-0h 0.93 (0.91-0.95) 0.96 (0.9-0.99) 0.3 
s-cTnI Siemens Ultra    
0h 0.91 (0.89-0.92) 0.94 (0.9-0.96)    0.07 
1h 0.93 (0.92-0.95) 0.96 (0.94-0.98) 0.1 
0h + ∆1h-0h 0.92 (0.91-0.94) 0.95 (0.93-0.97) 0.2 
s-cTnI Beckman Accu    
0h 0.89 (0.88-0.91) 0.94 (0.91-0.97) 0.1 
1h 0.93 (0.90-0.95) 0.97 (0.93-0.99) 0.2 
0h + ∆1h-0h 0.93 (0.91-0.95) 0.96 (0.92-0.98) 0.3 
hs-cTnI Beckman Accu    
0h 0.91 (0.89-0.93) 0.94 (0.91-0.97) 0.3 
1h 0.93 (0.90-0.95) 0.97 (0.93-0.99) 0.1 
0h + ∆1h-0h 0.93 (0.91-0.95) 0.97 (0.93-0.99) 0.3 
a Morning: 11:00 P.M. – 2:00 P.M. 
b Evening = 2:00 P.M. – 11:00 P.M. 
AUC=Area Under the Curve; Δ=absolute change between baseline and 1h 
 
 
 
 
 
 
 
 Table 2B: Comparison of diagnostic accuracy for AMI as quantified by the area under 
the receiver-operating characteristics curve in morning and evening presenters 
amongst early presenting patients (≤3h since chest pain onset) 
 
 AUC (95%CI) AUC (95%CI)  
 Morninga Eveningb P-value 
s-cTnT Abbott Architect    
0h 0.87 (0.84-0.90) 0.91 (0.85-0.95) 0.4 
1h 0.95 (0.92-0.97) 0.96 (0.91-0.99) 0.7 
0h + ∆1h-0h 0.94 (0.92-0.97) 0.96 (0.93-0.97) 0.7 
s-cTnI Siemens Ultra    
0h 0.89 (0.87-0.91) 0.95 (0.92-0.97) 0.02 
1h 0.94 (0.92-0.95) 0.97 (0.94-0.98) 0.2 
0h + ∆1h-0h 0.93 (0.91-0.94) 0.96 (0.93-0.98) 0.3 
s-cTnI Beckman Accu    
0h 0.85 (0.81-0.88) 0.93 (0.87-0.97) 0.1 
1h 0.94 (0.91-0.96) 0.97 (0.91-0.99) 0.5 
0h + ∆1h-0h 0.94 (0.91-0.96) 0.96 (0.90-0.99) 0.6 
hs-cTnI Beckman Accu    
0h 0.89 (0.85-0.92) 0.93 (0.87-0.97) 0.4 
1h 0.91 (0.88-0.94) 0.97 (0.91-0.99) 0.2 
0h + ∆1h-0h 0.94 (0.91-0.97) 0.96 (0.91-0.99) 0.6 
a Morning: 11:00 P.M. – 2:00 P.M. 
b Evening = 2:00 P.M. – 11:00 P.M. 
AUC=Area Under the Curve; Δ=absolute change between baseline and 1h 
 
 
 
 
 
 
  
 Figures 
 
Figure 1: Median cTn concentrations at baseline in morning and evening presenters 
with non-cardiac chest pain, shown for all 4 assays 
 
Figure 2: Diagnostic accuracy for acute myocardial infarction in morning and evening 
presenters as quantified by the area under the receiver-operating characteristic curves 
using four (high)-sensitive cTnI assays  
